Summary
Global Markets Direct’s, ‘Influenza B Infections - Pipeline Review, H2 2016’, provides an overview of the Influenza B Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Influenza B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza B Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Influenza B Infections
- The report reviews pipeline therapeutics for Influenza B Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Influenza B Infections therapeutics and enlists all their major and minor projects
- The report assesses Influenza B Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Influenza B Infections
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Influenza B Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Influenza B Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc.
Altravax, Inc.
Aphios Corporation
BioClonetics Immunotherapeutics, Inc.
ContraFect Corporation
Humabs BioMed SA
Johnson & Johnson
Medicago Inc.
MedImmune, LLC
Mucosis B.V.
Sanofi Pasteur SA
Vaxart, Inc.
Zydus Cadila Healthcare Limited
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Influenza B Infections Overview 8
Therapeutics Development 9
Pipeline Products for Influenza B Infections - Overview 9
Pipeline Products for Influenza B Infections - Comparative Analysis 10
Influenza B Infections - Therapeutics under Development by Companies 11
Influenza B Infections - Therapeutics under Investigation by Universities/Institutes 12
Influenza B Infections - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Influenza B Infections - Products under Development by Companies 16
Influenza B Infections - Products under Investigation by Universities/Institutes 17
Influenza B Infections - Companies Involved in Therapeutics Development 18
AbbVie Inc. 18
Altravax, Inc. 19
Aphios Corporation 20
BioClonetics Immunotherapeutics, Inc. 21
ContraFect Corporation 22
Humabs BioMed SA 23
Johnson & Johnson 24
Medicago Inc. 25
MedImmune, LLC 26
Mucosis B.V. 27
Sanofi Pasteur SA 28
Vaxart, Inc. 29
Zydus Cadila Healthcare Limited 30
Influenza B Infections - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
AL-18 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
APP-0205 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
APP-309 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
CF-403 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
CR-8033 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
CR-8071 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
CR-9114 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Fluad (quadrivalent) - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
FluGEM - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
influenza [serotype B] vaccine - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
influenza [serotypes A, B] (split virion, tetravalent) vaccine - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
influenza [serotypes A, B] (virus like particle) vaccine - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Monoclonal Antibody for Influenza B - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Monoclonal Antibody for Influenza B Infections - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
VXABYW-10 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Influenza B Infections - Dormant Projects 66
Influenza B Infections - Discontinued Products 67
Influenza B Infections - Product Development Milestones 68
Featured News & Press Releases 68
Dec 17, 2015: Vaxart Announces Enrollment of First Patient in Influenza B Phase 1 Trial 68
Mar 11, 2011: Sanofi Pasteur And Daiichi Sankyo Announce Voluntary Recall Of Hemophilus Influenza Type B Conjugate Vaccine 69
Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71
List of Tables
Number of Products under Development for Influenza B Infections, H2 2016 9
Number of Products under Development for Influenza B Infections - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Influenza B Infections - Pipeline by AbbVie Inc., H2 2016 18
Influenza B Infections - Pipeline by Altravax, Inc., H2 2016 19
Influenza B Infections - Pipeline by Aphios Corporation, H2 2016 20
Influenza B Infections - Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016 21
Influenza B Infections - Pipeline by ContraFect Corporation, H2 2016 22
Influenza B Infections - Pipeline by Humabs BioMed SA, H2 2016 23
Influenza B Infections - Pipeline by Johnson & Johnson, H2 2016 24
Influenza B Infections - Pipeline by Medicago Inc., H2 2016 25
Influenza B Infections - Pipeline by MedImmune, LLC, H2 2016 26
Influenza B Infections - Pipeline by Mucosis B.V., H2 2016 27
Influenza B Infections - Pipeline by Sanofi Pasteur SA, H2 2016 28
Influenza B Infections - Pipeline by Vaxart, Inc., H2 2016 29
Influenza B Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 30
Assessment by Monotherapy Products, H2 2016 31
Assessment by Combination Products, H2 2016 32
Number of Products by Stage and Target, H2 2016 34
Number of Products by Stage and Mechanism of Action, H2 2016 35
Number of Products by Stage and Route of Administration, H2 2016 37
Number of Products by Stage and Molecule Type, H2 2016 39
Influenza B Infections - Dormant Projects, H2 2016 66
Influenza B Infections - Discontinued Products, H2 2016 67
List of Figures
Number of Products under Development for Influenza B Infections, H2 2016 9
Number of Products under Development for Influenza B Infections - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy Products, H2 2016 31
Assessment by Combination Products, H2 2016 32
Number of Products by Targets, H2 2016 33
Number of Products by Stage and Targets, H2 2016 33
Number of Products by Routes of Administration, H2 2016 36
Number of Products by Stage and Routes of Administration, H2 2016 36
Number of Products by Molecule Types, H2 2016 38
Number of Products by Stage and Molecule Types, H2 2016 38
